Destiny Pharma to Deliver Presentation at the European Society of Clinical Microbiology and Infectious Disease conference on XF-73 Nasal Gel and the Use of Post-Operative Antibiotics in Cardio-vascular Surgery Patients.
GS Verde acquire Anderson Shaw Corporate Finance
20th August 2024 JPJ: GSV ISIN: GB00B0M0J665 GS Verde acquire Anderson Shaw Corporate Finance The GS Verde Group, a UK & Ireland based dealmaking business, has expanded with the acquisition of West Midlands based Anderson Shaw Corporate Finance. This is the 3rd acquisition by GS Verde Group, as part of its buy and build strategy and is the latest in numerousannouncements so far […]
Interim Results for the Six Months Ended 30 June 2024
Released : 01/08/2024 07:00 RNS Number : 6863Y BiVictriX Therapeutics PLC 01 August 2024 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, […]
Destiny Pharma plc shares now trading on JP Jenkins
JP Jenkins LtdDestiny Pharma plc shares now trading on JP Jenkins 13-Aug-2024 / 07:00 GMT/BSTThe issuer is solely responsible for the content of this announcement. 13th Aug 2024 JPJ: DEST ISIN: GB00B60BD277 Destiny Pharma plc (“Destiny Pharma” or “the Company”) Shares now trading on JP Jenkins London, UK, 13th Aug 2024 – Destiny Pharma plc […]
Proposed voluntary cancellation of admission of Ordinary Shares to trading on AIM
RNS Number : 9863Z BiVictriX Therapeutics PLC 12 August 2024 This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018. With the publication of this announcement via a Regulatory Information Service, this inside information […]
Last Day of Dealings on AIM
Destiny Pharma plc(“Destiny Pharma” or “the Company”) Last Day of Dealings on AIM Brighton, United Kingdom ‐ 12 August 2024 ‐ Destiny Pharma plc (AIM: DEST), a clinical stage biotechnology company focused on the development and commercialisation of novel medicines to prevent and cure life‐threatening infections, reminds shareholders that the last day of trading in Destiny […]
Reconstruction Capital ii Limited – Annual Report and Audited Financial Statements 2023
Fulcrum returns to profitability following major strategic turnaround
The Group is pleased to report growth and a return to profitability as part of its strategic turnaround, which is delivering sustainable, progressive improvements across its operating divisions. Financial highlights • Performance was in line with management targets • Revenue increased 5.5% to £53.4m (2023: £50.6m) • Adjusted EBITDA* of £(0.5)m (2023: £(6.2)m) • Operating Profit of £0.5m (2023: Operating Loss of £24.6m) *Adjusted EBITDA is Operating Profit excluding the impact of exceptional items, other net gains, fair value gains […]
#6 Newsletter – JP Jenkins
Sixth Edition No Summer Holidays Here. This month we announced another new client – Superdry (Well done to all the team), alongside this we saw the announcements from Sondrel, i(x) Net Zero and Destiny Pharma Limited who intend to join JPJ very soon. We are delighted to announce the following new admissions to JP Jenkins: […]
#5 Newsletter – JP Jenkins
Fifth Edition This month we announced another new client (Lexington Gold Warrants), saw the announcement of Superdry PLC joining JPJ and lots of celebratory drinks / awards. Hoorah! We are delighted to announce the following new admissions to JP Jenkins: Lexington Gold (JPJ: LEXW): LEX announces its Warrants (https://lnkd.in/dCnT99cx) have been admitted to trade on […]
